Literature DB >> 20613478

Lumbar intrathecal administration of the quaternary lidocaine derivative, QX-314, produces irritation and death in mice.

Stephan K W Schwarz1, Helen M-C Cheung, Craig R Ries, Sang Mook Lee, Jimmy T C Wang, Bernard A MacLeod.   

Abstract

BACKGROUND: We recently found that peripheral administration of the quaternary lidocaine derivative, QX-314, produces long-lasting sensory and motor blockade in animals. The goal of this study was to test whether intrathecal QX-314 has similar properties.
METHODS: We conducted a randomized, double-controlled, blinded study with female CD-1 mice. Animals in the treatment group received lumbar intrathecal QX-314 (0.5-10 mM; volume, 2 microl; each concentration, n = 6). Normal saline and lidocaine (70 mM) served as negative and positive controls (each group, n = 12), respectively. Animals were tested for up to 3 h for lumbosacral neural blockade and observed for adverse effects.
RESULTS: No animal injected with saline and 11 of 12 (92%) animals injected with lidocaine displayed reversible lumbosacral motor blockade (P < 0.001). QX-314 (5 mM) produced motor blockade in four of the six (67%) and sensory blockade in five of the six animals (83%; P < 0.05 vs. saline). However, six of the six mice (100%) at 5 mM QX-314 and five of the six (83%) at 10 mM exhibited marked irritation; one of the six animals at 5 mM (17%) and two of the six at 10 mM (33%) died. We observed no neural blockade without adverse effects in any animal injected with QX-314. All animals injected with saline and 11 of the 12 (92%) animals injected with lidocaine demonstrated normal behavior.
CONCLUSION: Lumbar intrathecal QX-314 concentration-dependently produced irritation and death in mice, at lower concentrations than those associated with robust motor blockade. Although QX-314 did produce long-lasting neural blockade, these findings indicate that QX-314 is unlikely to be a suitable candidate for spinal anesthesia in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20613478     DOI: 10.1097/ALN.0b013e3181dfd31b

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

1.  Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review.

Authors:  D P Roberson; A M Binshtok; F Blasl; B P Bean; C J Woolf
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Differential effects of peripheral versus central coadministration of QX-314 and capsaicin on neuropathic pain in rats.

Authors:  Jun Shen; Lyle E Fox; Jianguo Cheng
Journal:  Anesthesiology       Date:  2012-08       Impact factor: 7.892

3.  Silencing Transient Receptor Potential Vanilloid Receptor Subtype I-containing Sensory Neurons to Treat Bone Cancer Pain.

Authors:  Christopher M Peters
Journal:  Anesthesiology       Date:  2016-07       Impact factor: 7.892

Review 4.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Duration and local toxicity of sciatic nerve blockade with coinjected site 1 sodium-channel blockers and quaternary lidocaine derivatives.

Authors:  Sahadev A Shankarappa; Itay Sagie; Jonathan H Tsui; Homer H Chiang; Cristina Stefanescu; David Zurakowski; Daniel S Kohane
Journal:  Reg Anesth Pain Med       Date:  2012 Sep-Oct       Impact factor: 6.288

6.  Prolonged Duration Topical Corneal Anesthesia With the Cationic Lidocaine Derivative QX-314.

Authors:  Alan G Woodruff; Claudia M Santamaria; Manisha Mehta; Grant L Pemberton; Kathleen Cullion; Daniel S Kohane
Journal:  Transl Vis Sci Technol       Date:  2019-10-17       Impact factor: 3.283

Review 7.  Neurological perspectives on voltage-gated sodium channels.

Authors:  Niels Eijkelkamp; John E Linley; Mark D Baker; Michael S Minett; Roman Cregg; Robert Werdehausen; François Rugiero; John N Wood
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

8.  Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Front Pharmacol       Date:  2011-10-04       Impact factor: 5.810

9.  Acid solution is a suitable medium for introducing QX-314 into nociceptors through TRPV1 channels to produce sensory-specific analgesic effects.

Authors:  He Liu; Hong-Xing Zhang; Hui-Yan Hou; Xian-Fu Lu; Jing-Qiu Wei; Chun-Guang Wang; Li-Cai Zhang; Yin-Ming Zeng; Yong-Ping Wu; Jun-Li Cao
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

10.  Co-Application of Eugenol and QX-314 Elicits the Prolonged Blockade of Voltage-Gated Sodium Channels in Nociceptive Trigeminal Ganglion Neurons.

Authors:  Sung-Min Hwang; Kihwan Lee; Sang-Taek Im; Eun Jin Go; Yong Ho Kim; Chul-Kyu Park
Journal:  Biomolecules       Date:  2020-11-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.